NasdaqGS - Delayed Quote USD

Adaptive Biotechnologies Corporation (ADPT)

2.6100 +0.0100 (+0.38%)
At close: April 25 at 4:00 PM EDT
2.6399 +0.03 (+1.15%)
After hours: April 25 at 6:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
170,276.0000
170,276.0000
185,308.0000
154,344.0000
98,382.0000
Cost of Revenue
75,553.0000
75,553.0000
57,909.0000
49,301.0000
22,530.0000
Gross Profit
94,723.0000
94,723.0000
127,399.0000
105,043.0000
75,852.0000
Operating Expense
296,329.0000
296,329.0000
327,585.0000
314,009.0000
228,669.0000
Operating Income
-201,606.0000
-201,606.0000
-200,186.0000
-208,966.0000
-152,817.0000
Net Non Operating Interest Income Expense
1,731.0000
1,731.0000
-182.0000
1,668.0000
6,590.0000
Other Income Expense
-25,429.0000
-25,429.0000
--
--
--
Pretax Income
-225,304.0000
-225,304.0000
-200,368.0000
-207,298.0000
-146,227.0000
Net Income Common Stockholders
-225,250.0000
-225,250.0000
-200,191.0000
-207,279.0000
-146,227.0000
Diluted NI Available to Com Stockholders
-225,250.0000
-225,250.0000
-200,191.0000
-207,279.0000
-146,227.0000
Basic EPS
-1.36
-1.56
-1.40
-1.48
-1.11
Diluted EPS
-1.36
-1.56
-1.40
-1.48
-1.11
Basic Average Shares
143,921.8660
144,383.2940
142,515.9170
140,354.9150
131,216.4680
Diluted Average Shares
143,921.8660
144,383.2940
142,515.9170
140,354.9150
131,216.4680
Total Operating Income as Reported
-227,035.0000
-227,035.0000
-200,186.0000
-208,966.0000
-152,817.0000
Total Expenses
371,882.0000
371,882.0000
385,494.0000
363,310.0000
251,199.0000
Net Income from Continuing & Discontinued Operation
-225,250.0000
-225,250.0000
-200,191.0000
-207,279.0000
-146,227.0000
Normalized Income
-199,821.0000
-199,821.0000
-200,191.0000
-207,279.0000
-146,227.0000
Interest Income
15,531.0000
15,531.0000
4,056.0000
1,668.0000
6,590.0000
Interest Expense
13,800.0000
13,800.0000
4,238.0000
--
--
Net Interest Income
1,731.0000
1,731.0000
-182.0000
1,668.0000
6,590.0000
EBIT
-211,504.0000
-211,504.0000
-196,130.0000
-207,298.0000
-152,817.0000
EBITDA
-189,273.0000
-189,273.0000
-175,210.0000
-193,345.0000
-144,345.0000
Reconciled Cost of Revenue
55,021.0000
55,021.0000
38,688.0000
37,047.0000
15,761.0000
Reconciled Depreciation
22,231.0000
22,231.0000
20,920.0000
13,953.0000
8,472.0000
Net Income from Continuing Operation Net Minority Interest
-225,250.0000
-225,250.0000
-200,191.0000
-207,279.0000
-146,227.0000
Total Unusual Items Excluding Goodwill
-25,429.0000
-25,429.0000
--
--
--
Total Unusual Items
-25,429.0000
-25,429.0000
--
--
--
Normalized EBITDA
-163,844.0000
-163,844.0000
-175,210.0000
-193,345.0000
-144,345.0000
12/31/2020 - 6/27/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

FATE Fate Therapeutics, Inc.
3.8700
-10.00%
 
ADAP Adaptimmune Therapeutics plc
1.0600
-1.85%
 
ALLO Allogene Therapeutics, Inc.
2.8550
-6.09%
 
ABCL AbCellera Biologics Inc.
3.6300
-6.92%
 
EDIT Editas Medicine, Inc.
5.22
-2.43%
 
BEAM Beam Therapeutics Inc.
21.60
-5.01%
 
NTLA Intellia Therapeutics, Inc.
20.02
-5.43%
 
ADCT ADC Therapeutics SA
4.4400
-7.11%
 
AMLX Amylyx Pharmaceuticals, Inc.
1.7800
-5.32%
 
RPTX Repare Therapeutics Inc.
3.1500
-4.55%